Ardelyx (ARDX) Net Equity Issued and Repurchased (2013 - 2023)
Ardelyx (ARDX) posted Net Equity Issued and Repurchased of -$12000.0 for Q4 2023, down 100.02% on a QoQ basis from $58.4 million in Q3 2023, and down 100.06% year-over-year from $18.8 million in Q4 2022.
Ardelyx (ARDX) Net Equity Issued and Repurchased (2013 - 2023) Analysis & Trends
Ardelyx's Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at -$12000.0 for Q4 2023.
- Quarterly Net Equity Issued and Repurchased fell 100.06% year-over-year to -$12000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$12000.0 (down 100.01% YoY) and the FY2023 annual result came in at $119.2 million, up 66.47% from the prior year.
- Net Equity Issued and Repurchased was -$12000.0 for Q4 2023 at Ardelyx, down from $58.4 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $134.9 million in Q4 2019 and bottomed at -$12000.0 in Q4 2023.
- A 5-year average of $33.2 million and a median of $23.3 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
- Peak annual rise in Net Equity Issued and Repurchased reached 776.54% in 2023, while the deepest fall reached 100.06% in 2023.
- Ardelyx's Net Equity Issued and Repurchased stood at $134.9 million in 2019, then sank by 83.91% to $21.7 million in 2020, then increased by 15.21% to $25.0 million in 2021, then declined by 24.88% to $18.8 million in 2022, then slumped by 100.06% to -$12000.0 in 2023.
- Business Quant data shows ARDX's Net Equity Issued and Repurchased at -$12000.0 in Q4 2023, $58.4 million in Q3 2023, and $11.6 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Ardelyx | 1.24 Bn | 999.81 Mn | 89.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -12,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | 58.40 Mn |
| Sep 30, 2023 | 58.40 Mn |
| Jun 30, 2023 | 11.60 Mn |
| Jun 30, 2023 | 11.60 Mn |
| Mar 31, 2023 | 51.90 Mn |
| Mar 31, 2023 | 51.90 Mn |
| Dec 31, 2022 | 18.78 Mn |
| Dec 31, 2022 | 18.78 Mn |
| Sep 30, 2022 | 35.10 Mn |
| Sep 30, 2022 | 35.10 Mn |
| Jun 30, 2022 | 12.56 Mn |
| Jun 30, 2022 | 12.56 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Sep 30, 2021 | 4.74 Mn |
| Sep 30, 2021 | 4.74 Mn |